Investigational asuptegravir cut HIV-1 RNA by up to 2.36 log10 copies/mL in 10 days, and adding fostemsavir boosted CD4 gains in immunologic nonresponders.
|Videos|January 7, 2020
Are Transgender Women Underrepresented in Sexual Health Research?
Author(s)Contagion® Editorial Staff
Max Brito, MD, MPH, remarks on the underrepresentation of transgender women in HIV and other sexual health research.
Advertisement
Max Brito, MD, MPH, professor of medicine at the University of Illinois, remarks on the underrepresentation of transgender women in HIV and other sexual health research.
Interview Transcript (modified slightly for readability):
Contagion®: Is there a need for more consideration of transgender women when it comes to HIV and sexual health research?
Brito: Absolutely, much more research is needed in transgender women. We know there are not enough studies addressing the needs of this population. The care in general of transgender women, the targeted care, not only HIV, but for sexually transmitted diseases, preventive care, it's lacking, and so we need to pay more attention and research. I think this reflects the patient population that we serve at the clinic but it's also in research. I think there is an underrepresentation of transgender women in general and we need to do a better job of that.
Advertisement
Related to this article
Switching to once-daily bictegravir/lenacapavir kept adverse event rates similar to comparators and metabolic markers stable across comorbidity groups in ARTISTRY-1 and -2.
Karen B. Jacobson, MD, MPH, of Kaiser Permanente Northern California, presented data at IDWeek 2026 showing 58.2% of children younger than five years exposed to active hepatitis B in the home were exposed by someone other than their birth mother, a risk maternal screening alone would miss under the CDC’s revised birth dose recommendation.
In this first IDWeek 2026 roundup, oral olorofim matched AmBisome in invasive aspergillosis, aztreonam-avibactam held activity as MBL-producing CRE rose, pritelivir cut hospitalizations in refractory HSV, and zelicapavir shortened RSV symptoms in high-risk adults.
David Altarac, MD, discusses the 2026 IDSA guidance, which prioritizes sulbactam-durlobactam plus a carbapenem for invasive carbapenem-resistant Acinetobacter infections.
Investigational agent Zelicapavir cut time to complete RSV symptom resolution by up to a week and lowered hospitalization in high-risk adults.
Preliminary SABEDTIO data from IDWeek 2026 show early dual IV therapy cut prolonged S aureus bacteremia to 6% from 16%, with safe oral transition at 72 hours.
Alejandra Gurtman, MD, discussed the phase 2 data at IDWeek 2026 which showed the investigational 25-valent pneumococcal conjugate vaccine 25vPnC produced serotype 3 antibody levels about 15-fold higher than Prevnar 20 after the booster dose, targeting a serotype still behind 10.6% of invasive pneumococcal disease in US children younger than five years.
Advertisement
Advertisement
Trending on Contagion Live
1
Early Dual Therapy Shortens Staphylococcus aureus Bacteremia in SABEDTIO Trial
2
Ebola Update: DRC Outbreak Reaches 9735 Cases, Second Largest on Record
3
IDSA 2026 Guidance Makes Sulbactam-Durlobactam the Priority for CRAB Infections
4
ID Week Highlights Part 1
5